Erratum to: A Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly [Infect Dis Ther, Doi 10.1007/s40121-015-0076-8];A Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly

Infectious Diseases and Therapy

Volumn 4, Issue 4, 2015, Pages 459-487

  Mullikin, Mark ^a   Tan, Litjen ^b   Jansen, Jeroen P ^c   Van Ranst, Marc ^d   Farkas, Norbert ^e   Petri, Eckhardt ^f  

^a Novartis Vaccine   (United States)

^b Immunization Action Coalition   (United States)

^c Redwood Outcomes   (United States)

^d REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^e NOVARTIS PHARMA AG   (Switzerland)

^f Novartis Vaccine   (Germany)

Author keywords

Adjuvant; Clinical; Economic; Elderly; Influenza; Outcome; Quadrivalent; Trivalent; Vaccination; Vaccine

Indexed keywords

INFLUENZA VACCINE;

ADULT; AGED; ARTICLE; BRONCHITIS; CALIBRATION; CARDIOVASCULAR DISEASE; CHILD; DRUG EFFICACY; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; INFANT; INFLUENZA; INFLUENZA B; INFLUENZA VACCINATION; INFORMATION MODEL; NEWBORN; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; VERY ELDERLY;

EID: 84977109129     PISSN: 21938229     EISSN: 21936382     Source Type: Journal    
DOI: 10.1007/s40121-015-0090-x     Document Type: Erratum

References (67)

1. Meier CR, Napalkov PN, Wegmüller Y, Jefferson T, Jick H. Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom. Eur J Clin Microbiol Infect Dis. 2000;19:834–42.
2. Meyers DG. Myocardial infarction, stroke, and sudden cardiac death may be prevented by influenza vaccination. Curr Atheroscler Rep. 2003;2003(5):146–9.
3. Nicholson KG, Kent J, Hammersley V, Cancio E. Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden. BMJ. 1997;315:1060–4.
4. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. J Am Med Assoc. 2004;292:1333–40.
5. Menec VH, MacWilliam L, Aoki FY. Hospitalizations and deaths due to respiratory illnesses during influenza seasons: a comparison of community residents, senior housing residents, and nursing home residents. J Gerontol A Biol Sci Med Sci. 2002;57:M629–35.
6. Menec VH, Black C, MacWilliam L, Aoki FY. The impact of influenza-associated respiratory illnesses on hospitalizations, physician visits, emergency room visits, and mortality. Can J Public Health Rev Can Santé Publique. 2003;94:59–63.
7. Simonsen L, Fukuda K, Schonberger LB, Cox NJ. The impact of influenza epidemics on hospitalizations. J Infect Dis. 2000;181:831–7.
8. Mullooly JP, Bridges CB, Thompson WW, on behalf of the Vaccine Safety Datalink Adult Working Group, et al. Influenza- and RSV-associated hospitalizations among adults. Vaccine. 2007;25:846–55.
9. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. J Am Med Assoc. 2003;289:179–86.
10. Zamparo E, Little D. Immunogenicity and effectiveness of virosomal adjuvanted vaccines against influenza: a brief review of their utility in the elderly population. J Prev Med Hyg. 2011;52:116–9.
11. Viboud C, Miller M. Health benefits of universal influenza vaccination strategy. PLoS Med. 2008;5:e216.
12. McElhaney JE, Zhou X, Talbot HK, et al. The unmet need in the elderly: how immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines. Vaccine. 2012;30:2060–7.
13. Monto AS, Ansaldi F, Aspinall R, et al. Influenza control in the 21st century: optimizing protection of older adults. Vaccine. 2009;27:5043–53.
14. Nichol KL. Efficacy and effectiveness of influenza vaccination. Vaccine. 2008;26(Suppl. 4):D17–22.
15. Nichol KL. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine. 2003;21:1769–75.
16. Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis. 2007;7:658–66.
17. Sasaki S, Sullivan M, Narvaez CF, et al. Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. J Clin Invest. 2011;121:3109–19.
18. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis. 2009;200:172–80.
19. Coudeville L, Andre P, Bailleux F, Weber F, Plotkin S. A new approach to estimate vaccine efficacy based on immunogenicity data applied to influenza vaccines administered by the intradermal or intramuscular routes. Hum Vaccin. 2010;6:841–8.
20. Tricco AC, Chit A, Soobiah C, et al. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med. 2013;11:153.
21. DiazGranados CA, Denis M, Plotkin S. Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials. Vaccine. 2012;31:49–57.
22. ® quadrivalent): a review of its use in the prevention of disease caused by influenza A and B. Drugs. 2013;73:1587–94.
23. De Donato S, Granoff D, Minutello M, et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine. 1999;17:3094–101.
24. Squarcione S, Sgricia S, Biasio LR, Perinetti E. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. Vaccine. 2003;21:1268–74.
25. Mannino S, Villa M, Apolone G, et al. Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy. Am J Epidemiol. 2012;176:527–33.
26. Durando P, Icardi G, Ansaldi F. MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. Expert Opin Biol Ther. 2010;10:639–51.
27. Molinari N-AM, Ortega-Sanchez IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007;25:5086–96.
28. Annemans L. Methods for economic evaluations. In: Health economics for non-economists. Gent: Academia Press; 2008. p. 29–79.
29. Reed C, Meltzer MI, Finelli L, Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine. 2012;30:1993–8.
30. Centers for Disease Control and Prevention (CDC). Update: influenza activity—United States, 2010–11 season, and composition of the 2011–12 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2011;60:705–12.
31. Centers for Disease Control and Prevention (CDC). Update: influenza activity—United States, 2011–12 season and composition of the 2012–13 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2012;61:414–20.
32. Centers for Disease Control and Prevention (CDC). Influenza activity—United States, 2012–13 season and composition of the 2013–14 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2013;62:473–9.
33. Epperson S, Blanton L, Kniss K, on behalf of the Influenza Division NCfI, Respiratory Diseases CDC, et al. Influenza activity—United States, 2013–14 season and composition of the 2014–15 influenza vaccines. MMWR Morb Mortal Wkly Rep. 2014;63:483–90.
34. US Department of Commerce. Current Population Survey (CPS)—a joint effort between the Bureau of Labor Statistics and the Census Bureau—People and Households—US Census Bureau [online document]. US Census Bureau. 2012. http://www.census.gov/cps/. Accessed 27 Oct 2014.
35. Del Valle SY, Hyman JM, Hethcote HW, Eubank SG. Mixing patterns between age groups in social networks. Soc Netw. 2007;29:539–54.
36. Biggerstaff M, Cauchemez S, Reed C, Gambhir M, Finelli L. Estimates of the reproduction number for seasonal, pandemic, and zoonotic influenza: a systematic review of the literature. BMC Infect Dis. 2014;14:480.
37. Cowling BJ, Fang VJ, Riley S, Peiris JSM, Leung GM. Estimation of the serial interval of influenza. Epidemiology. 2009;20:344–7.
38. Fraser C, Donnelly CA, Cauchemez S, on behalf of the WHO Rapid Pandemic Assessment Collaboration, et al. Pandemic potential of a strain of influenza A (H1N1): early findings. Science. 2009;324:1557–61.
39. Centers for Disease Control and Prevention (CDC). Flu vaccination coverage, United States, 2013–14 Influenza Season/FluVaxView/Seasonal Influenza (Flu)/CDC [online document]. 2014. http://www.cdc.gov/flu/fluvaxview/coverage-1314estimates.htm. Accessed 27 Oct 2014.
40. Blyth CC, Jacoby P, Effler PV, on behalf of the WAIVE Study Team, et al. Effectiveness of trivalent flu vaccine in healthy young children. Pediatrics. 2014;133:1218–25.
41. Prosser LA. Cost-effectiveness of Influenza Vaccine [online document]. NIVS, May 16–17, 2012, Atlanta, GA, USA. National Adult Influenza Immun. Summit. http://www.izsummitpartners.org/summit/archive/2012-nivs/. Accessed 28 Oct 2014.
42. Talbird SE, Brogan AJ, Winiarski AP, Sander B. Cost-effectiveness of treating influenza-like illness with oseltamivir in the United States. Am J Health Syst Pharm. 2009;66:469–80.
43. Lloyd-Jones D, Adams RJ, Brown TM, on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, et al. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121:e46–215.
44. Lee GM, Salomon JA, LeBaron CW, Lieu TA. Health-state valuations for pertussis: methods for valuing short-term health states. Health Qual Life Outcomes. 2005;3:17.
45. Dyer MTD, Goldsmith KA, Sharples LS, Buxton MJ. A review of health utilities using the EQ-5D in studies of cardiovascular disease. Health Qual Life Outcomes. 2010;8:13.
46. Prosser LA, Ray GT, O’Brien M, Kleinman K, Santoli J, Lieu TA. Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine. Pediatrics. 2004;113:283–90.
47. Fryback DG, Dunham NC, Palta M, et al. US norms for six generic health-related quality-of-life indexes from the National Health Measurement study. Med Care. 2007;45:1162–70.
48. ftp.cdc.gov-/pub/health_Statistics/NCHS/Publications/NVSR/56_09/ [online document] [no date]. http://ftp.cdc.gov/pub/health_Statistics/NCHS/Publications/NVSR/56_09/. Accessed 15 June 2015.
49. Fisman DN, Tuite AR. Estimation of the health impact and cost-effectiveness of influenza vaccination with enhanced effectiveness in Canada. PLoS One. 2011;6:e27420.
50. Seasonal Flu [online document]. 2015. Flu.gov. http://www.flu.gov/about_the_flu/seasonal/index.html. Accessed 12 June 2015.
51. Centers for Medicare and Medicaid Services. Physician fee schedule. 2014. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched/index.html?redirect=/PhysicianFeeSched/. Accessed 22 July 2015.
52. Centers for Medicare and Medicaid Services. Clinical laboratory fee schedule. 2014. http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/clinlab.html. Accessed 22 July 2015.
53. Centers for Medicare and Medicaid Services. Average sales price (ASP) drug pricing files. 2014. http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2014ASPFiles.html. Accessed 22 July 2015.
54. Nichol KL, Tummers K, Hoyer-Leitzel A, Marsh J, Moynihan M, McKelvey S. Modeling seasonal influenza outbreak in a closed college campus: impact of pre-season vaccination, in-season vaccination and holidays/breaks. PLoS One. 2010;5:e9548.
55. Coburn BJ, Wagner BG, Blower S. Modeling influenza epidemics and pandemics: insights into the future of swine flu (H1N1). BMC Med. 2009;7:30.
56. Knipl DH, Röst G. Modelling the strategies for age specific vaccination scheduling during influenza pandemic outbreaks. Math Biosci Eng. 2011;8:123–39.
57. Damm O, Eichner M, Rose MA, et al. Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany. Eur J Health Econ. 2015;16:471–88.
58. Centers for Disease Control and Prevention (CDC). Prevention and Control of Seasonal Influenza with Vaccines/Health Professionals/Seasonal Influenza (Flu) [online document]. 2014. http://www.cdc.gov/flu/professionals/acip/index.htm. Accessed 30 Oct 2014.
59. DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371:635–45.
60. Izurieta HS, Thadani N, Shay DK, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. Lancet Infect Dis. 2015;15:293–300.
61. Centers for Medicare and Medicaid Services. Medicare Enrollment—National Trends 1966–2013. Medicare aged and disabled enrollees by type of coverage. All areas, as of July 1, 1966–2013. Hospital and/or Supplementary Medical Insurance, Medicare Enrollment Reports. Baltimore: Centers for Medicare and Medicaid Services; 2014.
62. Datamonitor Healthcare. Influenza vaccines forecast (No. DMKC0107117). London: Informa UK Ltd; 2014.
63. Baldo V, Baldovin T, Pellegrini M, et al. Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents. Clin Dev Immunol. 2010;2010:517198.
64. Ansaldi F, Zancolli M, Durando P, et al. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. Vaccine. 2010;28:4123–9.
65. Orsi A, Ansaldi F, de Florentiis D, et al. Cross-protection against drifted influenza viruses: options offered by adjuvanted and intradermal vaccines. Hum Vaccines Immunother. 2013;9:582–90.
66. Xue Y, Kristiansen IS, de Blasio BF. Modeling the cost of influenza: the impact of missing costs of unreported complications and sick leave. BMC Public Health. 2010;10:724.
67. Preaud E, Durand L, Macabeo B, on behalf of the Vaccines Europe Influenza Working Group, et al. Annual public health and economic benefits of seasonal influenza vaccination: a European estimate. BMC Public Health. 2014;14:813.